BioSpace News Archive

This new collaboration unites leaders in cystic fibrosis gene therapy, lentiviral development and production, and the treatment of respiratory diseases to develop the first gene therapy for cystic fibrosis.

A modern genetic test for a cancer patient contains more information than ever before: Too much, in fact, for modern digital medical records.

Neosanté Health Solutions raises awareness for babies and newborns suffering from episodes of irritability, agitation and crying for National Breastfeeding Awareness Month in August.

ASLAN Pharmaceuticals reported financial results for the quarter ended 30 June 2018 and provided an update on its clinical activities.

Top-line Results of Dose-Escalation Part to be Presented at ESMO 2018 Congress

Ascletis Pharma Inc. (1672.HK) announced today Ravidasvir is recommended by the World Health Organization (WHO) Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection (July 2018) as a future pan-genotypic direct-acting antivirals agent (DAA). Ascletis received the acceptance letter for Ravidasvir new drug application (NDA) from the China Food and Drug Administration (CFDA) on August 1.

The purchase price for this transaction consisted of cash, in addition to warrants.

This pre-clinical study examines the Immunotoxicology and anti-inflammatory properties of GB Sciences’ Cannabis-Containing Complex Formulas for Parkinson’s Disease in preparation for their clinical trial.

Upfront and milestone payments total up to $74.5M plus double-digit royalties

BioCryst Pharmaceuticals, Inc. announced that the Company has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for BCX7353 for the prevention of angioedema attacks in patients with hereditary angioedema (HAE).